Results 11 to 20 of about 318,819 (293)

Cytokine release syndrome in solid tumors [PDF]

Cancer
AbstractCytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to ...
David Synnott, David O’Reilly, Declan De Freitas, Jarushka Naidoo   +3 more
openaire   +4 more sources

Cytokine Release Syndrome: A Case Report [PDF]

Cureus
Although generally well tolerated, immune checkpoint inhibitors can occasionally lead to severe immune-related adverse events, including cytokine release syndrome (CRS), a condition resulting from excessive immune activation and cytokine secretion, specifically interleukin-6 (IL-6).
Silva, Inês Filipa, Salgueira, Sofia Gomes, Loureiro, Ana Isabel, Nascimento, Luisa, Gomes, Teresa   +4 more
openaire   +3 more sources

Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations [PDF]

Current Oncology
Background: Cytokine Release Syndrome (CRS) is a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs).
Panos Arvanitis, Andreas Tziotis, Spyridon Papadimatos, Dimitrios Farmakiotis   +3 more
doaj   +2 more sources

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome. [PDF]

PLoS Computational Biology
Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for cancer treatment, although disease relapse and cytokine release syndrome (CRS) remain as frequent clinical challenges.
Daniela S Santurio, Luciana R C Barros, Ingmar Glauche, Artur C Fassoni   +3 more
doaj   +2 more sources

Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature

Clinical and Translational Radiation Oncology, 2022
We present the case of a 53-year-old woman treated with analgesic radiotherapy for a multiple myeloma bone lesion of the forearm. After a first fraction of 5 Gray (Gy), she presented with an acute respiratory syndrome with fever a few hours after the ...
Axel Cailleteau, Cyrille Touzeau, Bastien Jamet, Valentine Guimas, Emmanuel Jouglar, Stéphane Supiot   +5 more
doaj   +1 more source

Cytokine Release Syndrome Following Blinatumomab Therapy [PDF]

Cureus, 2022
New therapeutic solutions have emerged in the last few decades with the growth and expansion of the field of cancer research. Amongst these new agents, immunotherapy has been prominent, particularly regarding the treatment of hematologic malignancies.
Ojemolon, Pius E, Kalidindi, Sunaina, Ahlborn, Taylor A, Aihie, Osaigbokan P, Awoyomi, Moyosoluwa I   +4 more
openaire   +2 more sources

Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease

IJU Case Reports, 2022
Introduction Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections.
Daiji Takamoto, Hajime Sasaki, Hiroshi Kataoka, Fumihiro Kodama, Haruka Higuchi, Tetsuo Hirano, Yusuke Takada, Shigeru Harada, Hiroshi Harada, Hiroshi Tanaka   +9 more
doaj   +1 more source

Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report

Kidney Medicine, 2021
Chimeric antigen receptor T (CAR-T) cell treatment is a rapidly emerging therapy for relapsed/refractory hematologic malignancies. Although cytokine release syndrome is a common complication, a concomitant development of biopsy-proven collapsing ...
Ratna Acharya, Biljana Horn, Xu Zeng, Kiran Upadhyay   +3 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]

, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core   +1 more source